In this ongoing Phase 1a/1b clinical study, AB-729 led to an approximately 1 log10 mean HBsAg decline at week 12 with a single 60 mg dose. All subjects responded to therapy with a minimum HBsAg decline of -0.62 log10 and a maximum HBsAg decline of -2.14 log10 at week 12.
In March 2020, we announced positive preliminary Phase 1a/1b clinical trial results for AB-729, and in May 2020 we announced additional positive single-dose Phase 1a/1b clinical trial results for AB-729.
Arbutus believes that the magnitude and continuous reduction in HBsAg achieved with a single 60 mg dose of AB-729 has the potential to provide an important competitive advantage by allowing us to use a low and well-tolerated dose, as well as less frequent dosing.
AB-729 was generally safe and well tolerated through 12 weeks after a single dose with normal ALTs throughout the follow up period.